Full Text View
Tabular View
Study Results
Related Studies
Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial
This study has been terminated.
( Imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded external medical monitor. )
Study NCT00414726   Information provided by Massachusetts General Hospital

First Received on December 21, 2006.   Last Updated on October 28, 2011   History of Changes
Results First Received: July 1, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Ischemic Stroke
Interventions: Drug: NBO (Normobaric Oxygen)
Drug: Room Air

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
February 2007-June 2009

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Normobaric Oxygen Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
Room Air Room Air, inhaled at 30-45L/min via a facemask for 8 hours

Participant Flow:   Overall Study
    Normobaric Oxygen     Room Air  
STARTED     43     42  
COMPLETED     43     41  
NOT COMPLETED     0     1  
Withdrawal by Subject                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Normobaric Oxygen Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
Room Air Room Air, inhaled at 30-45L/min via a facemask for 8 hours

Baseline Measures
    Normobaric Oxygen     Room Air     Total  
Number of Participants  
[units: participants]
 		  43     42     85  
Age  
[units: years]
Mean ± Standard Deviation 		  74.1  ± 14     73.4  ± 14     73.7  ± 14  
Gender  
[units: participants]
 		     
Female     27     17     44  
Male     16     25     41  
Ethnicity (NIH/OMB)  
[units: participants]
 		     
Hispanic or Latino     0     6     6  
Not Hispanic or Latino     42     36     78  
Unknown or Not Reported     1     0     1  
Race (NIH/OMB)  
[units: participants]
 		     
American Indian or Alaska Native     0     0     0  
Asian     1     2     3  
Native Hawaiian or Other Pacific Islander     0     0     0  
Black or African American     2     1     3  
White     40     39     79  
More than one race     0     0     0  
Unknown or Not Reported     0     0     0  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Primary Safety Outcome Measure is a Comparison of the Change in National Institutes of Health Stroke Scale (NIHSS) Scores From Baseline to 24 Hours (After Therapy) in the Two Groups.   [ Time Frame: 24 hours ]
  Show Outcome Measure 1

2.  Primary:   Primary Efficacy Outcome Measure is a Comparison of the Change in National Institutes of Health Stroke Scale (NIHSS) Scores From Baseline to 4 Hours (During Therapy) in the Two Groups.   [ Time Frame: 4 hours after starting treatment ]
  Show Outcome Measure 2


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
THESE ARE *PRELIMINARY* RESULTS.  


Results Point of Contact:  
Name/Title: Aneesh B. Singhal, MD
Organization: Massachusetts General Hospital
phone: 617 726 8459
e-mail: asinghal@partners.org


Publications:
Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke. 2005 Apr;36(4):797-802. Epub 2005 Mar 10.
Kim HY, Singhal AB, Lo EH. Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol. 2005 Apr;57(4):571-5.
Singhal AB, Dijkhuizen RM, Rosen BR, Lo EH. Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. Neurology. 2002 Mar 26;58(6):945-52.
Singhal AB, Ratai E, Benner T, Vangel M, Lee V, Koroshetz WJ, Schaefer PW, Sorensen AG, Gonzalez RG. Magnetic resonance spectroscopy study of oxygen therapy in ischemic stroke. Stroke. 2007 Oct;38(10):2851-4. Epub 2007 Aug 30.
Singhal AB. Oxygen therapy in stroke: past, present, and future. Int J Stroke. 2006 Nov;1(4):191-200. Review.
Fujiwara N, Murata Y, Arai K, Egi Y, Lu J, Wu O, Singhal AB, Lo EH. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. BMC Neurosci. 2009 Jul 15;10:79.


Responsible Party: Aneesh B. Singhal, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00414726     History of Changes
Other Study ID Numbers: R01NS051412, P50NS051343
Study First Received: December 21, 2006
Results First Received: July 1, 2010
Last Updated: October 28, 2011
Health Authority: United States: Food and Drug Administration





Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services